182 related articles for article (PubMed ID: 27580559)
1. Effectiveness of Imatinib Mesylate Treatment in a Patient with Dermatofibrosarcoma Protuberans with Pulmonary and Pancreatic Metastases.
Tatai T; Gomi D; Fukushima T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S; Koizumi T; Sano K
Intern Med; 2016; 55(17):2507-11. PubMed ID: 27580559
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
[TBL] [Abstract][Full Text] [Related]
3. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.
Labropoulos SV; Fletcher JA; Oliveira AM; Papadopoulos S; Razis ED
Anticancer Drugs; 2005 Apr; 16(4):461-6. PubMed ID: 15746584
[TBL] [Abstract][Full Text] [Related]
4. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
[TBL] [Abstract][Full Text] [Related]
5. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S
Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744
[TBL] [Abstract][Full Text] [Related]
6. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.
Rubin BP; Schuetze SM; Eary JF; Norwood TH; Mirza S; Conrad EU; Bruckner JD
J Clin Oncol; 2002 Sep; 20(17):3586-91. PubMed ID: 12202658
[TBL] [Abstract][Full Text] [Related]
7. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
[TBL] [Abstract][Full Text] [Related]
8. Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review.
Navarrete-Dechent C; Mori S; Barker CA; Dickson MA; Nehal KS
JAMA Dermatol; 2019 Mar; 155(3):361-369. PubMed ID: 30601909
[TBL] [Abstract][Full Text] [Related]
9. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.
Stacchiotti S; Pedeutour F; Negri T; Conca E; Marrari A; Palassini E; Collini P; Keslair F; Morosi C; Gronchi A; Pilotti S; Casali PG
Int J Cancer; 2011 Oct; 129(7):1761-72. PubMed ID: 21128251
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.
Kérob D; Porcher R; Vérola O; Dalle S; Maubec E; Aubin F; D'Incan M; Bodokh I; Boulinguez S; Madelaine-Chambrin I; Mathieu-Boue A; Servant JM; de Kerviler E; Janin A; Calvo F; Pedeutour F; Lebbe C
Clin Cancer Res; 2010 Jun; 16(12):3288-95. PubMed ID: 20439456
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate.
Kambayashi Y; Kasahara Y; Ohuchi K; Amagai R; Hashimoto A; Asano Y; Fujimura T
Dermatol Ther; 2022 Oct; 35(10):e15736. PubMed ID: 35898161
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).
Stacchiotti S; Pantaleo MA; Negri T; Astolfi A; Tazzari M; Dagrada GP; Urbini M; Indio V; Maestro R; Gronchi A; Fiore M; Dei Tos AP; Conca E; Palassini E; Vincenzi B; Grosso F; Pilotti S; Castelli C; Casali PG
Clin Cancer Res; 2016 Feb; 22(4):837-46. PubMed ID: 26261104
[TBL] [Abstract][Full Text] [Related]
14. [New molecular approaches in dermatofibrosarcoma protuberans].
Kaya G
Rev Med Suisse; 2009 Jul; 5(211):1519-24. PubMed ID: 19694363
[TBL] [Abstract][Full Text] [Related]
15. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
[TBL] [Abstract][Full Text] [Related]
16. [Management for locally advanced dermatofibrosarcoma protuberans in Togo].
Amavi AK; Dossouvi T; Padaro E; Adabra K; Dosseh ED
Bull Cancer; 2018 Apr; 105(4):333-334. PubMed ID: 29502795
[No Abstract] [Full Text] [Related]
17. Dermatofibrosarcoma Protuberans.
Allen A; Ahn C; Sangüeza OP
Dermatol Clin; 2019 Oct; 37(4):483-488. PubMed ID: 31466588
[TBL] [Abstract][Full Text] [Related]
18. Orbital dermatofibrosarcoma protuberans with intracranial extension preceded by recurrent leiomyoma of the orbit: a case report.
Bashir S; Tariq M; Aslam HM; Hashmi AS; Malik B; Amin A; Mumtaz S
J Med Case Rep; 2015 Apr; 9():96. PubMed ID: 25924890
[TBL] [Abstract][Full Text] [Related]
19. Current treatment options in dermatofibrosarcoma protuberans.
Lemm D; Mügge LO; Mentzel T; Höffken K
J Cancer Res Clin Oncol; 2009 May; 135(5):653-65. PubMed ID: 19205737
[TBL] [Abstract][Full Text] [Related]
20. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications.
Llombart B; Sanmartín O; López-Guerrero JA; Monteagudo C; Serra C; Requena C; Poveda A; Vistós JL; Almenar S; Llombart-Bosch A; Guillén C
Histopathology; 2009 Jun; 54(7):860-72. PubMed ID: 19635106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
